Dissecting cross‐lineage tumourigenesis under p53 inactivation through single‐cell multi‐omics and spatial transcriptomics

Xinru Wang(First Affiliated Hospital Zhejiang University), Yuqing Mei(First Affiliated Hospital Zhejiang University), Xueyi Wang(First Affiliated Hospital Zhejiang University), Hanyu Wu(First Affiliated Hospital Zhejiang University), Renying Wang(First Affiliated Hospital Zhejiang University), Peijing Zhang(Institute for Stem Cell Biology and Regenerative Medicine), Guodong Zhang(First Affiliated Hospital Zhejiang University), Jiaqi Li(First Affiliated Hospital Zhejiang University), Mengmeng Jiang(Zhejiang Chinese Medical University), Xing Fang(First Affiliated Hospital Zhejiang University), Lifeng Ma(First Affiliated Hospital Zhejiang University), Yuan Liao(First Affiliated Hospital Zhejiang University), Danmei Jia(First Affiliated Hospital Zhejiang University), Haofu Niu(First Affiliated Hospital Zhejiang University), E Weigao(First Affiliated Hospital Zhejiang University), Haide Chen(Zhejiang Chinese Medical University), Lei Yang(First Affiliated Hospital Zhejiang University), Shuang Zhang(First Affiliated Hospital Zhejiang University), Tingyue Zhang(First Affiliated Hospital Zhejiang University), Yincong Zhou(Zhejiang University), Qi Zhang(First Affiliated Hospital Zhejiang University), He Huang(Zhejiang Institute of Mechanical and Electrical Engineering), Hongwei Ouyang(Institute for Stem Cell Biology and Regenerative Medicine), Ming Chen(Zhejiang University), Tingbo Liang(First Affiliated Hospital Zhejiang University), Jinrong Peng(Zhejiang University), Jingjing Wang(Zhejiang Chinese Medical University), Guoji Guo(Zhejiang Chinese Medical University), Xiaoping Han(First Affiliated Hospital Zhejiang University)
Clinical and Translational Medicine
August 31, 2025
Cited by 1Open Access
Full Text

Abstract

BACKGROUND: Tumour suppressor genes, exemplified by TP53 (encoding the human p53), function as critical guardians against tumourigenesis. Germline TP53-inactivating mutations underlie Li-Fraumeni syndrome, a hereditary cancer predisposition disorder characterised by early-onset pan-tissue malignancies. However, the context-dependent tumour-suppressive mechanisms of p53 remain incompletely elucidated. This study aims to investigate the disruption of cellular homeostasis and tumourigenic mechanisms following p53 inactivation across distinct cell lineages. METHODS: Trp53 (encoding mouse p53) knockout mouse model was employed to study molecular alterations under p53-deficient conditions. Multi-omics analyses - including single-cell transcriptomics, single-cell ATAC-seq, spatial transcriptomics, whole genome sequencing, and CUT&Tag - were integrated to construct a Trp53 functional cell landscape. Deep learning-based gene network models were employed to reconstruct p53 regulatory networks and simulate in silico perturbations caused by p53 loss. RESULTS: Our analyses revealed transitional dynamics in immune, stromal, and epithelial cells from normal physiology to p53-deficient states and subsequent tumourigenesis. These transitions implicated critical pathways such as cell cycle regulation, stress response, metabolic reprogramming, and immune modulation, displaying both lineage-conserved and lineage-specific features. Tumour-prone cell populations exhibiting elevated differentiation plasticity were identified across lineages within tumourigenic trajectories. Spatial transcriptomic profiling confirmed the emergence of thymic tumour-initiating T-cell clusters characterised by deterministic chromatin architectural disruptions under p53-loss pressure. Notably, we uncovered a recurrent upregulation signature of ribosomal protein genes as an early pivotal molecular event preceding malignant transformation in p53-deficient oncogenesis. Finally, we decoded the p53 downstream regulatory network and computationally evaluated the perturbation effects of genetic inactivation at single-cell resolution. CONCLUSIONS: Our results elucidate the multiscale consequences of p53 inactivation while providing valuable resources for understanding tumour predisposition associated with p53-inactivating mutations and developing clinical interception strategies. KEY POINTS: Construction of a Trp53 functional cell landscape utilising single-cell multi-omics and spatial omics technologies. Reconstruction of p53 downstream regulatory relationships with lineage heterogeneity via machine learning-based gene network modelling. Dissection of shared and lineage-specific features during cross-lineage tumourigenesis under p53 deficiency.


Related Papers

No related papers found

Powered by citation graph analysis